NSECredit Rating1d ago · 17 Nov 2026, 07:30 pm
Credit Rating
Thirumalai Chemicals Limited · TIRUMALCHM
✦ AI SummaryRating Change
Thirumalai Chemicals Limited has informed the Exchange about Credit Rating. ICRA notes the improvement in consolidated profitability in H1FY2027, with operating profit increasing to Rs. 71.2 crore compared to the preceding losses, owing to improvement in PAN-OX spreads. However, the coverage indicators remain under pressure and sustained improvement in profitability remains a key monitorable going forward.
Analysis Scores
Earnings Impact6/10
Growth Catalyst5/10
Governance Concern2/10
Regulatory Risk4/10
Balance Sheet Risk7/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Thirumalai Chemicals Limited has informed the Exchange about Credit Rating
Attachments (1)
📄pdf
Download →
TIRUMALCHM1_17112026192906_SELetterCreditRatingletter17112026SD.pdf
View document text
Registered Office:
“THIRUMALAI HOUSE”,
Plot No. 101-102, Road No. 29,
Sion (East), Mumbai – 400 022, India
PHONE: +91 – 22– 43686200
FAX +91 – 22 – 24011699
E- MAIL: thirumalai@thirumalaichemicals.com
Website: www.thirumalaichemicals.com
(AN ISO 9001, 14001, 50001/ HACCP & FSSC 22000 CERTIFIED COMPANY)
CIN: L24100MH1972PLC016149
TCL/SE061/2026-27
November 17, 2026
The National Stock Exchange of India Ltd. BSE Limited
Listing Department Department of Corporate Services
Exchange Plaza, Bandra Kurla Complex Floor 25, Phiroze Jeejeebhoy Towers
Bandra (East) Dalal Street
Mumbai 400 051 Mumbai 400 001
Scrip code: TIRUMALCHM Scrip code: 500412
Dear Sir/ Madam,
Sub.: Sub: Intimation under Regulations 30 of the Securities and Exchange Board of
India (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Credit
Rating
Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015 (“the Regulations”), we inform you of the rating
action, based on the intimation received from ICRA Limited dated November 16, 2026, as
summarized below:
Instrument Previous Current Rating Action Reason /
Rated Rated Rationale
Amount Amount
(Rs. In cr.) (Rs. In cr.)
Long term - Fund 445.00 445.00 [ICRA]BBB
based - Term loan (Negative)
Long term Fund based 334.50 334.50 [ICRA]BBB
-Working capital (Negative)
facilities
Reaffirmed –
Short term –Non-fund- (684.00) (755.00) [ICRA]A3+
based Facilities Letter
Long term/Short term - 350.00 275.00 [ICRA]BBB Attached
Unallocated limits (Negative)
Short term –Non-fund- 175.00 175.00 [ICRA]A3+
based Facilities
Non-convertible 100.00 100.00 [ICRA]BBB
debentures (Negative);
Registered Office:
“THIRUMALAI HOUSE”,
Plot No. 101-102, Road No. 29,
Sion (East), Mumbai – 400 022, India
PHONE: +91 – 22– 43686200
FAX +91 – 22 – 24011699
E- MAIL: thirumalai@thirumalaichemicals.com
Website: www.thirumalaichemicals.com
(AN ISO 9001, 14001, 50001/ HACCP & FSSC 22000 CERTIFIED COMPANY)
CIN: L24100MH1972PLC016149
Kindly take the above information in your records.
Thanking you,
Yours faithfully,
For Thirumalai Chemicals Limited
Aditya Sharma
Company Secretary & Compliance officer
Encl: As above
November 16, 2026
Thirumalai Chemicals Limited: Update on Material Event
Summary of rating action
Previous rated Current rated
Financial Sector
Instrument* amount amount Rating outstanding
Regulator#
(Rs. crore) (Rs. crore)
Long term - Fund based -
445.00 445.00 [ICRA]BBB(Negative) RBI
Term loan
Long term - Fund based -
334.50 334.50 [ICRA]BBB(Negative) RBI
Working capital facilities
Short term – Non-fund
(684.00) (755.00) [ICRA]A3+ RBI
based facilities
Long term/Short term -
350.00 275.00 [ICRA]BBB(Negative)/[ICRA]A3+ RBI
Unallocated limits
Short term – Non-fund
175.00 175.00 [ICRA]A3+ RBI
based facilities
Non-convertible
100.00 100.00 [ICRA]BBB(Negative) MCA
debentures
Total 1,404.50 1329.50
*Instrument details are provided in Annexure I; # SEBI’s grievance redressal/dispute resolution and SEBI investor protection mechanisms such as SCORES and
ODR shall not be available for activities and instruments which fall under the regulatory purview of Financial Sector Regulators other than SEBI.
Rationale
Material Event
Thirumalai Chemicals Limited (TCL) announced its Q2FY2027 results on November 05, 2026. ICRA notes the improvement in
consolidated profitability in H1FY2027, with operating profit increasing to Rs. 71.2 crore compared to the preceding losses,
owing to improvement in PAN-OX spreads. However, the coverage indicators remain under pressure and sustained
improvement in profitability remains a key monitorable going forward. ICRA takes note of the various refinancing options
under consideration by the company to reduce the pressure on coverage metrics and improve liquidity. The overall liquidity
profile is expected to be supported by refinancing initiatives, other divestments, and operational cash flows. The timely
refinancing of the loan for US project remains a key rating sensitivity and monitorable.
Additionally, the full commissioning and subsequent ramp-up of the US project, TCL Specialties LLC, will remain a key
monitorable over the near to medium term. Upon stabilisation, the project is expected to improve the company’s product mix
and geographical diversification, supporting an expansion in operating margins.
Please refer to the following link for the previous detailed rationale, which covers the key rating drivers and their descriptions,
liquidity position, and rating sensitivities. Click here.
www. icra .in
Page |
Sensitivity Label : Public
Analytical approach
Analytical Approach Comments
Corporate Credit Rating Methodology
Applicable rating methodologies
Chemicals
Parent/Group support Not applicable
The ratings are based on the consolidated financial profile of the company. The details of the
Consolidation/Standalone
consolidation are provided in Annexure II
About the company
TCL started its operations in 1976 at Ranipet in Tamil Nadu as a single product petrochemical company, manufacturing phthalic
anhydride (PAN), with a production capacity of 6,000 TPA. Over the years, TCL has expanded its total PAN manufacturing
capacity to ~1,72,000 TPA, including Dahej phase 1, and has added other products to its portfolio, which includes food additives
such as Malic acid and Fumaric acid, and PAN derivatives such as Di-ethyl phthalate (DEP) and Phthalimide (PID).
In FY2025, the Dahej phase II project was commissioned which added ~96,000-TPA capacity of PAN and ~10,000 TPA of fumaric
acid. TCL caters to customers in the construction, auto, paint, food, personal care and pharmaceutical industries. It also has a
maleic anhydride (MAN) manufacturing facility in Malaysia under its step-down subsidiary, Optimistic Organic Sdn. Bhd, which
is largely non-operational. (OOSB). The company is also expected to fully commence its US project in Q4FY2027, which is a
facility for manufacturing MAN and food acids.
Key financial indicators
TCL Consolidated FY2025 FY2026 H1 FY2027*
Operating income 2,051.4 1,735.5 1,143.1
PAT -46.1 -167.9 -78.0
OPBDIT/OI 2.7% -1.4% 6.2%
PAT/OI -2.2% -9.7% -6.8%
Total outside liabilities/Tangible net worth (times) 2.3 2.0 2.3
Total debt/OPBDIT (times) 32.1 -91.3 15.6
Interest coverage (times) 1.1 -0.3 0.7
Source: Company, ICRA Research; All ratios as per ICRA’s calculations; Amount in Rs. Crore;
PAT: Profit after tax; OPBDIT: Operating profit before depreciation, interest, taxes and amortisation; Amount in Rs. crore; *Results
Status of non-cooperation with previous CRA: Not applicable
Any other information: None
www. icra .in
Page |
Sensitivity Label : Public
Rating history for past three years
Chronology of rating history
Current rating (FY2027)
for the past 3 years
Date & rating in FY2026 Date & rating in
Date & rating in FY2027 Date & rating in FY2025
Instru- Amount FY2024
ment
Type rated November Jan 12, Nov 25,
August 13, June 09, Aug 26, May 27, Feb 14, Aug 04,
(Rs. crore) 16, 2026 2025 Dec 03, 2024 May 24, 2024
2026 2026 2025 2025 2024 2023
2026
Term Long [ICRA]BBB [ICRA]BBB [ICRA]BBB+ [ICRA]BBB+ [ICRA]A [ICRA]A+ [ICRA]A+ [ICRA]A+
1 445.00 (Nega- (Nega- (Nega-
loans term (Negative) (Negative) (Negative) (Negative) (Negative) (Negative) (Negative) (Stable)
tive) tive) tive)
Fund [ICRA]A- [ICRA]A- [ICRA]A+
Long [ICRA]BBB [ICRA]BBB [ICRA]BBB+ [ICRA]BBB+ [ICRA]A [ICRA]A+ [ICRA]A+ [ICRA]A+
2 based lim- 334.50 (Nega- (Nega- (Nega-
term (Negative) (Negative) (Negative) (Negative) (Negative) (Negative) (Negative) (Stable)
its tive) tive) tive)
Non-fund
Short
3 based fa- 175.00 [ICRA]A3+ [ICRA]A3+ [ICRA]A2 [ICRA]A2 [ICRA]A2+ [ICRA]A2+ [ICRA]A2+ - - - -
term
cilities
Long [ICRA]BBB+ [ICRA]BBB+ [ICRA]A- [ICRA]A-
[ICRA]BBB [ICRA]BBB [ICRA]A(Neg- [ICRA]A+(Neg- [ICRA]A+(Neg-
Unallo- term/ (Negative) (Negative) (Nega- (Nega-
4 275.00 (Negative)/ (Negative)/ ative)/ ative)/ ative)/ - -
cated Short / / tive) / tive) /
term [ICRA]A2 [ICRA]A2 [ICRA]A2+ [ICRA]A2+
Non-fund
based fa- Sh
[Showing first 8,000 characters — download PDF for full document]